SGC-CLK-1: A chemical probe for the Cdc2-like kinases CLK1, CLK2, and CLK4

Author:

Tiek Deanna,Wells Carrow I.,Schröder Martin,Song Xiao,Alamillo-Ferrer Carla,Goenka Anshika,Iglesia Rebeca,Lu Minghui,Hu Bo,Kwarcinski Frank,Sintha Parvathi,de Silva Chandi,Hossain Mohammad AnwarORCID,Picado Alfredo,Zuercher William,Zutshi Reena,Knapp Stefan,Riggins Rebecca B.,Cheng Shi-Yuan,Drewry David H.

Funder

NIH

Northwestern University Feinberg School of Medicine

Publisher

Elsevier BV

Subject

General Engineering

Reference50 articles.

1. Trends in kinase drug discovery: targets, indications and inhibitor design;Attwood;Nat. Rev. Drug Discov.,2021

2. Pharmacology of modulators of alternative splicing;Bates;Pharmacol. Rev.,2017

3. Roles and mechanisms of alternative splicing in cancer - implications for care;Bonnal;Nat. Rev. Clin. Oncol.,2020

4. Abstract 5691: SM08502, a novel, small-molecule CDC-like kinase (CLK) inhibitor, demonstrates strong antitumor effects and Wnt pathway inhibition in castration-resistant prostate cancer (CRPC) models;Bossard;Cancer Res.,2020

5. Hypoxia leads to significant changes in alternative splicing and elevated expression of CLK splice factor kinases in PC3 prostate cancer cells;Bowler;BMC Cancer,2018

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3